Medline ® Abstract for Reference 41
of 'Treatment of androgenetic alopecia in men'
Randomized Placebo-Controlled, Double-Blind, Half-Head Study to Assess the Efficacy of Platelet-Rich Plasma on the Treatment of Androgenetic Alopecia.
Alves R, Grimalt R
Dermatol Surg. 2016 Apr;42(4):491-7.
BACKGROUND: Platelet-rich plasma (PRP) was identified as having a beneficial effect in alopecia and has been postulated as a new therapy for androgenetic alopecia (AGA).
OBJECTIVE: To assess the efficacy of PRP for the treatment of AGA.
MATERIALS AND METHODS: This was a randomized, placebo-controlled, double-blind study in 25 patients with AGA. Platelet-rich plasma was injected in half-head and the other half-head with placebo. Each patient received a total of 3 treatments of PRP, 1 month apart.
RESULTS: Six months after the first treatment with PRP, significant differences were seen in mean anagen hairs (67.6±13.1), telogen hairs (32.4±13.1), hair density (179.9±62.7), and terminal hair density (165.8±56.8) when compared with baseline (p<.05). Platelet-rich plasma was also found to increase hair density when comparing with the control side (p<.05). For the first time, the authors found a correlation between anagen hairs and patients>40 years and beginning of AGA≥25 years old (p<.05) and hair density and male sex, age≤40 years, positive family history of AGA and>10 years of duration of the disease (p<0.05).
CONCLUSION: Application of PRP showed a positive effect on AGA and could be regarded as an adjuvant therapy for AGA.
Department of Dermatology, Universitat Internacional de Catalunya, Barcelona, Spain.